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Open access under CC BY license.It is now established that most of the 800 G-protein-
coupled receptors (GPCRs) are regulated by phos-
phorylation in a process that results in the recruitment
of arrestins, leading to receptor desensitization and the
activation of arrestin-dependent processes. This gener-
alized view of GPCR regulation, however, does not
provide an adequate mechanism for the control of
tissue-specific GPCR signalling. Here, we review the
evidence that GPCR phosphorylation is, in fact, a flex-
ible and dynamic regulatory process in which GPCRs
are phosphorylated in a unique manner that is associ-
ated with the cell type in which the receptor is
expressed. In this scenario, phosphorylation offers a
mechanism of regulating the signalling outcome of
GPCRs that can be tailored to meet a specific physio-
logical role.Introduction
The earliest studies of GPCR phosphorylation determined
the involvement ofmore than one protein kinasemediating
multi-site phosphorylation [1,2]. In these studies, the b2-
adrenoceptor was shown to be phosphorylated at low levels
of receptor occupancy by protein kinase (PK) A in a process
that resulted in the phosphorylation of sites in the third
intracellular loop and C-terminal tail of both the agonist-
occupied and -unoccupied receptor. However, at high ago-
nist occupancy the receptor was phosphorylated addition-
ally by members of the G-protein-coupled-receptor kinase
(GRK) family at sites in the C-terminal tail that were
distinct from the PKA sites [3–5]. The key features of these
studies were that, first, very different protein kinases are
in operation that have very different mechanisms of acti-
vation. Second, that these protein kinases phosphorylate
distinct sites on the receptor with different kinetics. Third,
the signalling consequences of these phosphorylation
events have some overlapping features (e.g. they both
result in receptor desensitization) but they also have
unique features (e.g. phosphorylation mediated by the
GRKs, but not that by PKA, mediates receptor internaliz-
ation and arrestin recruitment) [2].
Hence, these studies carried out on the b2-adrenoceptor
over a decade ago provided clear evidence for differentialCorresponding author: Tobin, A.B. (tba@le.ac.uk).
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comes. However, the possibility that this process might
be employed in a tissue-specific manner to tailor specific
signalling outcomes of GPCR subtypes in physiological cell
types has, until recently, been largely overlooked [6]. This
can be attributed to the desire to determine a ‘unifying
hypothesis’ that explains the regulation of all GPCR sub-
types regardless of the cell type in which they are
expressed. Thus, all but a few GPCRs are considered to
be phosphorylated by one or more of the family of seven
GRKs (GRK1 through to GRK7) in a process that results in
the uncoupling of the receptor from its G protein and the
recruitment of one of four subtypes of arrestin [7,8].
Whereas this process is undoubtedly in operation, it belies
the complex nature of the phosphorylation of GPCRs. It
also does not offer a mechanism by which GPCRs can be
regulated in a tissue-specific maner. It seems likely that
the same receptor expressed in different tissue types will
be regulated in a manner that reflects the receptors phys-
iological role. Therefore, a M2 muscarinic receptor, for
example, expressed on cardiac pacemaker cells with con-
trol over contractile rates of the heart [9] would be expected
to have different regulatory features from the same re-
ceptor expressed in prejunctional parasympathetic
neurones in the lung [10].
Recent studies have indicated that the process of re-
ceptor phosphorylation and arrestin recruitment does not
always conform to the simplified model described but
might, in fact, be heterogeneous, offering a broad range
of signalling outcomes.
The heterogeneity of receptor–arrestin interaction
It is widely accepted that the primary function of receptor
phosphorylation is to promote the recruitment of arrestin
to the activated receptor [7]. Whereas this process has been
clearly resolved in the case of rhodopsin interaction with
arrestin1 [11], it is far harder to conceptionalize how the
diverse nature of phosphorylation on the 800 non-visual
GPCRs, which show very little sequence homology in their
intracellular domains [12], results in the same outcome,
namely arrestin recruitment. This conundrum has led
some to suggest that phosphorylation simply increases
bulk negative charge on the intracellular surface of the
receptor and it is this that is important in the recruitmentAvailable online 6 July 2008 413
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phorylation site [11].
However, there is considerable variation in the ability of
receptors to interact with arrestins. Despite the fact that
the b2-adrenoceptor is highly phosphorylated after agonist
stimulation, this receptor interacts with low affinity with
arrestins and shows preferential binding to arrestin3 over
arrestin2; these are characteristics described as attribu-
table to class A receptors [13]. This contrasts with class B
receptors (such as the V2 vasopressin receptor), which form
high-affinity complexes with both arrestin2 and arrestin3
that are sufficiently stable to bemaintained as the receptor
traffics to intracellular compartments after agonist occu-
pation [13]. The functional impact of this heterogeneity
might be profound because it is now clear that the arrestin
isotypes have distinct interacting partners and signalling
roles. In the case of the angiotensin AT1A receptor, which is
a class B receptor that recruits both arrestin2 and
arrestin3, it was found that only arrestin3 supports G-
protein-independent extracellular signal-related kinase
(ERK-1/2) activation. By contrast, both arrestin isotypes
support AT1A-receptor desensitization equally [14]. Thus,
the signalling outcome from arrestin recruitment to this
particular receptor will be determined by the balance of the
competition between arrestin2 and arrestin3 for inter-
action with the phosphorylated receptor. Furthermore,
recent proteomic analysis of the interacting partners with
the arrestins demonstrated that 71 proteins selectively
interacted with arrestin2, whereas a staggering 164 were
able to interact selectively with arrestin3 [15]. It is possibly
too early to determine the functional significance of these
findings but it, nevertheless, shows the potential differen-
tial cellular role of the two arrestin subtypes and the
impact that differential arrestin recruitment might have
in receptor signalling.
The heterogeneity in the relationship between receptor
phosphorylation and arrestin recruitment extends beyond
class A and class B receptors to extreme cases in which
receptor phosphorylation seems to play no part in arrestin
recruitment. Protease-activated receptor (PAR)-1 and sub-
stance P and leukotriene B4 receptors are examples of
receptors whereby arrestin binding is independent of re-
ceptor phosphorylation [16–18]. That this phenomenon is
more widespread is illustrated by studies on the orexin
OX1 and PAR-2 receptors, in which removal of putative
phospho-acceptor sites has no significant effect on the
ability of these receptors to interact with arrestins [19,20].
An explanation for this heterogeneity lies in the fact
that receptor–arrestin interaction consists of two distinct
components [11]. The first is the interaction of arrestin
with the agonist-occupied conformation of the receptor.
This occurs via the ‘activation’ sensor, which is proposed
to consist of multiple points of contact between the agonist-
occupied receptor and the concave surface of arrestin [21].
The second component is the interaction of phosphates
contained on the phosphorylated receptor with the ‘phos-
phate’ sensor situated in the polar core of arrestin [22].
Disruption of the salt bridge at the polar core results in
conformational changes in arrestin that promote a high-
affinity receptor–arrestin interaction [11]. In the case of
rhodopsin–arrestin1, the co-operative binding shown414between the activation and phosphate sensors increases
the affinity of arrestin1 for the receptor by an order of
magnitude [23]. By contrast, despite the hyperphosphory-
lated nature of the agonist-occupied non-visual GPCRs, the
contribution made by the interaction with the phosphate
sensor on arrestin2 or arrestin3 is modest, often only
resulting in a 2–3 fold increase in affinity [11,23]. However,
where phosphorylation seems to have no role in arrestin
recruitment, it seems that the interaction of the active
conformation of the receptor with the arrestin-activation
sensor is itself sufficient to provide a functional receptor–
arrestin complex.
In some receptor subtypes the need for phosphorylation
to promote arrestin recruitment has been eliminated by
the presence of negatively charged residues that function
as phosphomimetics. An acidic cluster in the C-terminal
tail of the chemokine receptor D6 [24] and an aspartate in
the third intracellular loop of the luteinizing hormone and
choriogonadotropin receptor [25] are thought to interact
with the phosphate sensor in arrestin and therebymediate
phosphorylation-independent arrestin interaction. Inter-
estingly, despite the absence of a requirement for phos-
phorylation in the recruitment of arrestin these receptors
are still phosphorylated [26,27]. The role of receptor phos-
phorylation in these instances is unknown but it is likely to
extend beyond arrestin recruitment.
Can GRKs regulate differential signalling via differential
phosphorylation?
The GRKs have a broad substrate specificity favouring
serine and threonine residues contained within acidic-rich
regions and share many GPCR substrates [12]. It is, how-
ever, not clear whether the various members of the GRK
family can phosphorylate different sites on the agonist-
occupied receptor.
This question has recently been addressed in an elegant
study that used fluorescence resonance energy transfer
between a cyan-fluorescent-protein-tagged b2-adrenocep-
tor and yellow-fluorescent-protein-tagged arrestin3 to
visualize, in real time, the two components of arrestin
recruitment; namely, a rapid phosphorylation-indepen-
dent association followed by a slower phosphorylation-de-
pendent phase [28]. Surprisingly, preventing GRK-
mediated phosphorylation had no effect on the overall
recruitment of arrestin3 to the receptor. Rather, it was
the kinetics of the slow phase of arrestin recruitment that
was regulated by GRK phosphorylation [28]. The subtlety
of the role of each of the GRKs was revealed by small
interfering RNA (siRNA) silencing of eachGRK subtype –it
was shown that GRK2 mediates the majority of b2-adre-
noceptor phosphorylation, but it is GRK6 activity that has
the most impact on the rate of arrestin recruitment [28].
Interestingly, GRK6 is the only one of the GRKs to phos-
phorylate the receptor at residues 355 and 356 on the C-
terminal tail. These studies, therefore, raise the possibility
that the GRKs might be able to differentially phosphor-
ylate the b2-adrenoceptor with the result of determining
different rates of arrestin recruitment.
Not only might the rates of arrestin recruitment be
dependent on the subtype of GRK involved in receptor
phosphorylation but, judging by studies on the V2 vaso-
Review Trends in Pharmacological Sciences Vol.29 No.8pressin and AT1A angiotensin receptors, so might the
signalling function of arrestin [29,30]. In the case of these
receptors, GRK2 and GRK3 are again the primary GRK
subtypes responsible for agonist-dependent phosphoryl-
ation. However, inhibition of GRK2 and GRK3 activity
has little effect on arrestin-mediated ERK-1/2. This con-
trasts with inhibition of GRK5 and GRK6 activity, which
has no significant effect on receptor phosphorylation but,
nevertheless, results in a reduction in arrestin-dependent
ERK-1/2 activation. The argument posed by the authors
was that GRK2 and GRK3 are able to phosphorylate sites
on the receptor that confer a conformation on arrestin that
is not conducive to the activation of the ERK-1/2 pathway.
By contrast, GRK5- and GRK6-mediated phosphorylation
results in a conformation of arrestin that promotes acti-
vation of ERK-1/2 signalling [29,30]. A similar distinction
between the signalling properties of receptor phosphoryl-
ation via GRK2/3 and GRK5/6 has recently been reported
for the b2-adrenoceptor [31] and follicle-stimulating hor-
mone (FSH) receptor [32].
The notion that arrestin might adopt a variety of con-
formations depending on the type of phosphorylation sites
on the receptor is supported by evidence that the nature of
the complex formed between arrestin1 and rhodopsin
depends on the number of sites on rhodopsin that are
phosphorylated [33]. Furthermore, in the case of the N-
formylpeptide receptor, arrestin binding is influenced by
the phosphorylation status within two serine and thero-
nine clusters. Here, phosphorylation within one cluster
mediates a different arrestin-dependent effect on receptor
function compared with that observed after phosphoryl-
ation of the other cluster [34].
The complexity of GPCR phosphorylation
Numerous studies using a myriad of techniques such as
mass spectrometry [35], phosphopeptide mapping
[36,37], phosphospecific antibodies [5,38] and mutagen-
esis [4,32,39] have determined that GPCRs are multiply
phosphorylated after agonist occupation. These phos-
phorylation events occur largely at the C-terminal tail
or third intracellular loops of receptors [4,32,39,40], but
can also occur within regions of the first and second
intracellular loops [41,42]. Whereas the majority of re-
ceptor phospho-acceptor sites are in serine-and-threo-
nine-rich regions of the intracellular domains, there is
also evidence that GPCRs are phosphorylated on tyrosine
residues [43,44] in a manner that can, in some instances,
generate classical phosphotyrosine protein-interaction
motifs [45]. It is now clear that this diversity of phos-
phorylation is mediated by receptor kinases that extend
beyond the GRKs, PKA and PKC to include protein
kinase CK2 [37,46], CK1a [47–49], PKB (also known as
Akt) [50–53] and receptor tyrosine kinases [52]. In the
case of the b1- and b2-adrenoceptors, for example, these
receptor subtypes are phosphorylated by members of the
GRK family, PKA and PKC [1,12,54], but in addition
these receptors have been demonstrated to be phosphory-
lated by the insulin receptor, insulin-like receptor and
PKB [52]. Hence, GPCRs can be phosphorylated by
multiple protein kinases at multiple sites throughout
their intracellular domains in a manner that can beconsidered as providing a broad dynamic range in which
receptor signalling can be modulated.
Thus, one mechanism by which cell-type-specific regu-
lation of receptor signalling could be achieved is by cells
employing a restricted complement of receptor kinases in
receptor phosphorylation (Box 1). This could be achieved
either by differential expression, activation or scaffolding
of the receptor kinases.
The potential to regulate the signalling outcome by
differential phosphorylation is illustrated by studies on
the M3 muscarinic receptor, which is phosphorylated not
only by GRK2 and GRK6 [49,55,56] but also by CK1a
[47,49] and protein kinase CK2 [37]. Tryptic phosphopep-
tide maps have revealed that these protein kinases can
phosphorylate distinct sites on the third intracellular loop
of the M3 muscarinic receptor [37]. siRNA knockdown of
CK2 results in an 72% reduction in receptor phosphoryl-
ation; however, this does not affect the internalization or
coupling of the receptor to the ERK-1/2 pathway [37]. By
contrast, inhibition of CK2 activity results in enhanced
Jun-kinase signalling [37]. These results demonstrate that
phosphorylation of the M3 muscarinic receptor by CK2 has
a specific impact on the signalling of the receptor to the
Jun-kinase pathway but no impact on other phosphoryl-
ation-dependent pathways. These data are consistent with
earlier studies that established that GRK-mediated phos-
phorylation of theM3muscarinic receptor is responsible for
receptor internalization and desensitization, and that
CK1a activity regulates the coupling of the receptor to
calcium signalling [49] and the ERK-1/2 pathway
[48,55,57]. Thus, in the case of the M3 muscarinic receptor,
there is evidence that site-specific phosphorylation, by a
range of receptor kinases, can result in specific signalling
outcomes that are dependent on the protein kinase
employed in the phosphorylation [37,49].
This conclusion can also be drawn from an elegant
study of the somatostatin sst2A receptor, in which, despite
the fact that the majority of agonist-regulated phos-
phorylation occurs at serine residues (80%), it is
‘minority’ phosphorylation on threonine residues
throughout the third intracellular loop and C-terminal
tail that is important for efficient arrestin recruitment
and internalization [40]. Desensitization of the sst2A re-
ceptor, however, requires both theronine and serine phos-
pho-acceptor sites [40]. Thus, in a manner similar to that
described for the M3 muscarinic receptor, differential
phosphorylation of the sst2A receptor results in differen-
tial signalling outcomes.
Physiological consequences of differential GPCR
phosphorylation
If the notion that differential receptor phosphorylation is
employed to mediate cell-type-specific receptor signalling
is true, it should be possible to detect cell-type-specific
receptor phosphorylation. The low expression levels of
GPCRs havemade this very challenging, but recent studies
have determined cell-type-specific phosphorylation of the
M3 muscarinic receptor [37]. In these studies, tryptic-
phosphopeptide maps from M3 muscarinic receptors
expressed in Chinese hamster ovary (CHO) cells and
natively expressed in cerebellar granule neurones have415
Box 1. Model for differential receptor phosphorylation encoding differential signalling outcomes
Figure I depicts a single GPCR subtype that is able to be phosphorylated by three different protein kinases at distinct sites on the C-terminal tail
and third intracellular loop. These hypothetical protein kinases are shown to be employed in different combinations resulting in different
phosphorylation profiles or phosphorylation signatures.
The phosphorylation signature translates to a code (the phosphorylation code) that directs the signalling outcome of the receptor. In this
process, GPCR phosphorylation is a flexible regulatory mechanism that can be tailored to suit the signalling requirements of a receptor in a given
cell type. Thus, the same receptor subtype expressed in three different tissues (labelled tissues A–C in Figure I) can show different signalling
outcomes based on differential receptor phosphorylation.
Figure I. Cell-type-specific phosphorylation of a GPCR by three different protein kinases.
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that there are common sites of phosphorylation of the
receptor between these cell types but, importantly, there
are also sites that are specifically phosphorylated depend-
ing on the cell type [37] (Figure 1). These studies, therefore,
demonstrated that the M3 muscarinic receptor is phos-
phorylated in a cell-type-specific manner. The phosphoryl-
ation signature might encode signalling properties on the
receptor where common phosphorylation events mediate
common regulatory features such as arrestin recruitment
and internalization and where cell-type-specific events416mediate specific signalling functions related to the special-
ized physiological role of the receptor.
This tissue-specific phosphorylation code might be the
result of the tissue-specific employment of receptor kinases
to provide a unique phosphorylation signature on the re-
ceptor (Box 1).
That such a mechanism might exist is illustrated by
work on knockout animals lacking the genes encoding
members of the GRK family, in which it has been estab-
lished that GRKs can be differentially employed in the
regulation ofmuscarinic receptor subtypes in the heart and
Figure 1. Differential phosphorylation of the M3 muscarinic receptor in CHO cells and cerebellar granule neurones. (a) Schematic representation of the generation of a
receptor phospho-peptide map that reveals a specific pattern of phospho-peptides referred to here as a phosphorylation signature. The receptor (e.g. M3 muscarinic) is
immunoprecipitated from cells labelled with [32P]-orthophosphate using a receptor-specific antibody. (1) The radiolabelled receptor is excised from the SDS–PAGE gel and
the gel slice is subjected to tryptic digest. (2) The resulting tryptic peptides are spotted onto a cellulose plate and the plate is subjected to electrophoresis in one dimension
and to ascending chromatography in the other dimension (for details, see Ref. [37]). (b) Shown are two phospho-peptide maps of the M3 muscarinic receptor. (i) The map
from the receptor isolated from CHO cells transfected with the mouse M3 muscarinic receptor. (ii) The map generated from the M3 muscarinic receptor endogenously
expressed in cerebellar granule neurones (CGNs). It can be seen that there are phospho-peptides that are common to the two maps (labelled with numbers) in addition to
phospho-peptides that are specific either to receptors isolated from CHO cells (open arrows) or from receptors isolated from CGNs (closed arrow). This experiment
demonstrates that the M3 muscarinic receptor does have a cell–type-specific phosphorylation signature. Figure reproduced, with permission, from Ref. [37].
Review Trends in Pharmacological Sciences Vol.29 No.8lung. In these studies, the postjunctional M2 muscarinic
receptors on airway smooth muscle were seen to be desen-
sitized by GRK5 [58]. However, neither prejunctional M2
receptors on parasympathetic neurones innervating the
lung nor M2 muscarinic receptors that are expressed in the
heart are regulated by GRK5 [58]. Furthermore, despite
the fact that M2 muscarinic receptors present on the air-
way smooth-muscle cells are regulated by GRK5, the M3
muscarinic receptors on the same smooth-muscle cells
seem not to be influenced by GRK5 activity [58]. These
in vivo studies provide evidence, at least in the case of
GRK5, that GPCR phosphorylation shows both subtype
specificity (i.e. M2 versus M3) and tissue specificity (i.e.
airway smooth muscle versus cardiac tissue).
Potential mechanisms that generate differential GPCR
phosphorylation
How receptor kinases, which are usually ubiquitously
expressed (such as GRK2, GRK5 and CK2), are regulated
in a manner that enables differential phosphorylation of
receptor subtypes is uncertain. It is, however, likely that
the relative expression levels of the kinases together with
specialized scaffolding proteins play an important part.
Certainly, the contribution made by the various membersof the GRK family to b2-adrenoceptor phosphorylation is
dependent on their relative expression levels and this, in
turn, influences the kinetics of arrestin recruitment to the
receptor [28]. Although studies of the comparative expres-
sion levels of the GRKs and arrestins in native tissues are
limited, there is evidence of changes in the expression
levels of these proteins during neuronal development
[59] and in neuropathology [60].
The role of scaffolding proteins in coordinating protein
phosphorylation is now well established [61]. The fact that
scaffolding has an important role in GPCR phosphorylation
is illustrated by the coordinated phosphorylation of the
b1-adrenoceptor by PKA through scaffolding provided by
the A-kinase-anchoring protein AKAP-79 [62,63]. It is
likely, therefore, that differential scaffolding of receptors
with receptor kinases, together with differences in the
relative expression levels of the receptor kinases, will con-
tribute to themechanism bywhich the sameGPCR subtype
can be differentially phosphorylated in different tissues.
Concluding remarks
A common feature of each GPCR subtype is that they can
couple to a plethora of signalling pathways. In a physiologi-
cal setting, however, these receptors are likely to activate417
Table 1. Examples of receptor site-specific phosphorylation and functional correlates
GPCR Possible phosphorylation
sites and motif
Region Kinase Cell type Function Refs
Angiotensin type
II AT1A
Thr332, Ser335, Thr336,
Ser338
C-terminal tail ND CHOa Internalization [65]
b1-adrenoceptor Ser412 3i-loop PKB (Akt) CHO, cardiac
myocytes
Internalization [66]
b2-adrenoceptor Thr384, Ser396, Ser401,
Ser407
C terminus GRK2 In vitro ND [67]
Thr384, Thr393, Ser396,
Ser401, Ser407, Ser411
GRK5 In vitro ND
Ser355, Ser356, Ser364 C terminus GRK HEK293 Desensitization [4]
Ser261, Ser262 (also
Ser345, Ser346)
3i-loop and/or
C-terminal tail
PKA COS-7 and/or
HEK293
Desensitization [4]
Tyr350 (also Tyr354,
Tyr364)
C terminus Insulin
receptor
DDT1MF2 Association with Grb2 and internalization,
inhibition of cAMP production
[45]
Tyr132, Tyr141 2i-loop IGF-1
receptor
DDT1MF2 Internalization [45]
Follitropin receptor
(FSH)
Thr369, Ser370, Ser371,
Thr376
1i-loop ND HEK293 Internalization. Contributes to desensitization [42]
Thr536, Thr541, Ser544,
Ser545, Ser546, Ser547,
Thr549
3i-loop ND HEK293 Contributes to desensitization [32]
Thr638, Thr640, Ser641,
Ser643, Thr644
C terminus ND HEK293 Internalization and desensitization [32]
M2 muscarinic N-cluster (Ser286–Ser290) 3i-loop ND HEK293 Internalization [68]
C-cluster (Thr307–Ser311) 3i-loop ND HEK293 Internalization and desensitization
M3 muscarinic Lys370–Ser425 3i-loop CK1a CHO ERK-1/2 activation [48]
Ser351-Arg-Ser-Ser-Asp-
Glu-Glu-Asp356
3i-loop CK2 CHO JNK kinase activation [37]
S1P1 (EDG-1) Thr236 3i-loop PKB (Akt) HUVEC Rac activation, cortical actin assembly,
chemotaxis, angiogenesis
[53]
HEK293
CHO
Somatostatin sst2A 80% of phosphorylation on
serine
3i-loop and/or
C-terminal tail
ND CHO Contributes to desensitization [40]
20% of phosphorylation on
threonine
3i-loop and/or
C-terminal tail
ND CHO Internalization and arrestin recruitment.
Contributes to desensitization
aAbbreviations: CHO, Chinese hamster ovary; COS-7, African green-monkey kidney cell line; DDT1MF2, a hamster vas deferens smooth-muscle cell line; EDG-1, endothelial
differentiation gene 1; Grb2, growth-factor receptor-bound protein 2; HEK, human embryonic kidney cell; HUVEC, human umbilical-vein endothelial cells; i-loop, intracellular
loop; IGF-1, insulin-like growth factor-1; JNK, c-Jun N-terminal; ND, not determined.
Review Trends in Pharmacological Sciences Vol.29 No.8just a small complement of their full signalling repertoire in
a manner that reflects their physiological role. The process
by which receptors mediate cell-type-specific signalling will
undoubtedly involve several factors including cell-type-
specific expression of downstream signalling components
(e.g. cyclases and phospholipases) and the nature of the
receptor-signalling complex [64].
In this review, we have considered the possibility that
GPCRs are able to be phosphorylated in a cell-type-specific
manner and that the site-specific phosphorylation of
GPCRs can regulate specific signalling outcomes
(Table 1). Hence, it is possible that one mechanism
employed by a cell to tailor GPCR signalling to suit a
specific physiological role might be receptor phosphoryl-
ation, which seems to have sufficient diversity and
dynamic range to accommodate the numerous physiologi-
cal demands placed on each GPCR subtype.
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